What this is, and what it is not. This review does not — and is not intended to — show that the BSI AI Catalyst Scanner is a reliable tool to be used on its own for investment decision-making. It is one input in a research process. Everything below is a
AI
Six of this week's ten featured names were in last week's report. That is not the scanner being lazy — it is what an August calendar looks like when a dozen companies all guided to "mid-2026" and the quarter is running out of days.
AI
The top of this week's list is a wreckage report. Karyopharm ($KPTI) takes the #1 slot down 80% on the month after a Phase 3 miss on July 30. Capricor ($CAPR) sits at #5 down 83% after an FDA advisory committee voted 9–3 against its drug on
AI
The tape going into August is a study in exhaustion. Look down this week's featured list and the striking thing isn't the catalysts — it's how many of these names are trading like the market has already given up on them. Beam sits at an
AI
Programming note — the weekly AI Catalyst Scanner will run through the end of August 2026, then pause. The economics of the weekly format have moved against it: the API and data costs behind each issue have risen steadily, and the honest reason we're not converting this into a
AI
This week's screen is dominated by a late-July-through-August PDUFA pileup — nine of ten featured names have FDA decisions or major data landing inside the next six weeks, and five of those cluster in a five-day stretch between July 26 and August 5. That'
Autoimmune
In vivo CAR-T just became biotech's hottest autoimmune bet: $14B committed, zero human readouts. We break down all four B-cell depletion modalities, the leaders, the risks, and what's buyable.
AI
This issue skews toward hard regulatory dates and, unusually, toward big pharma. Eight of the seventeen names carry a PDUFA or generic-drug action date, clustered between July 11 and August 17 — Celcuity, Capricor, Outlook, MannKind, NRx, Moderna, Merck, and Astellas all have the FDA calendar circled. That's
Analysis
Disclosure: I hold a bullish position in Altimmune (ALT) through call options expiring January 2027 — a leveraged, directional position that profits if the stock rises. Assume that gives me a financial interest in a favorable outcome and weigh this analysis accordingly. My positions may change at any time without notice.
Finding Undervalued Biotechs via Thorough Investigation and Sharing Tips
This week's slate is short, and the reason is mechanical rather than a lack of opportunity. The scanner only surfaces catalysts dated at least seven days forward from the scan date, and no more than 45 days out — a 7-to-45-day forward window. Anything with a
The XBI spent the back half of June grinding sideways after a sharp spring rally, and this week's scan reflects a tape that's rewarding regulatory clarity over clinical hope. The top of the board is unusually de-risked: the two highest-ranked names are sitting on
This week the tape, not the calendar, sets the mood. Almost every name on the featured board walks into its catalyst beaten down — RSIs clustered in the teens to mid-40s, twenty-one-day momentum negative across nine of the top ten. Celcuity is the sharpest example: a company with
The calendar does the heavy lifting this week. ENDO, EHA and the tail of ASCO converge in mid-June, stacking the kind of conference readouts that move small-cap biotech regardless of where the broad tape sits. Three of this week's featured names — Rezolute, MBX and Cellectis — present
The first PROTAC just got approved. Here's the science behind protein degradation, the money pouring in, the rival approaches, and the biotechs worth watching.
(Editor's note) I sincerely apologize for a data discrepancy in last week's scanner article, where information regarding BCAB and BCYC was inadvertently conflated. While the core ML/AI data sources remain accurate and unchanged, a temporary switch in my editorial processing tools caused a degradation in
June is arriving loaded. The next five weeks bring a concentrated cluster of pivotal Phase 3 readouts, two PDUFA dates, and the year's densest conference run — ASCO already behind us, with EHA, EULAR, ENDO, ADA, and SVS VAM all hitting in the next three weeks. XBI has been
The Setup Between late March and early May 2026, two private biotechs were acquired by Big Pharma for a combined $3.7B in upfront cash. Gilead paid $1.675B for Ouro Medicines and its BCMAxCD3 T-cell engager. UCB paid $2.0B for Candid Therapeutics and its dual CD19/BCMA
Five PDUFA dates over four weeks. MNKD on May 29, CING on May 31, IRWD on May 24, SPRO on June 18, ACHV on June 20 — FDA decisions spread across pediatric diabetes, ADHD, pediatric GI, antibiotics, and smoking cessation, with ASCO opening June 1 while two of those decisions are
Q1 2026 — of Q1 picks gained 15%+ within 45 days A full quarterly review of all top-10 BSI scanner picks from Jan WK1 (Jan 5) through Mar WK4 (Mar 20) — 12 weekly scans, 115 picks tracked. 📷 Snapshot date: May 8, 2026 — all 45-day windows fully matured Q1 Key
The XBI has been coughing up gains all week, with macro-driven risk-off sentiment pressuring even names with clean data behind them. The notable pattern this issue: several large-cap biotech names — INSM, GPCR, RLAY, IDYA — are appearing in the scanner in deeply oversold territory, RSIs running in the
The XBI remains highly sensitive to clinical execution this week, with the market brutally punishing regulatory ambiguity while heavily rewarding clean proof-of-concept data. We are seeing a distinct rotation toward niche specialists and away from crowded, undifferentiated platform plays. Heading into mid-May conferences like ASGCT and ATS,
